[Federal Register Volume 69, Number 167 (Monday, August 30, 2004)]
[Notices]
[Pages 52905-52906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-19702]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Government-owned Inventions; Availability for Licensing and 
Cooperative Research and Development Agreements (CRADAs)

AGENCY: National Institute for Occupational Safety and Health, Centers 
for Disease Control and Prevention, Technology Transfer Office, 
Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention named in this notice is owned by agencies of the 
United States Government and is available for licensing in the United 
States (U.S.) in accordance with 35 U.S.C. 207, and is available for 
cooperative research and development agreements (CRADAs) in accordance 
with 15 U.S.C. 3710, to achieve expeditious commercialization of 
results of federally funded research and development. U.S. and foreign 
patent applications are expected to be filed in the near future, to 
extend market coverage for U.S. companies, and may also be available 
for licensing.

ADDRESSES: Licensing information may be obtained by writing to Suzanne 
Seavello Shope, J.D., Technology Licensing and Marketing Scientist, 
Technology Transfer Office, Centers for Disease Control and Prevention 
(CDC), Mailstop K-79, 4770 Buford Highway, Atlanta, GA 30341, telephone 
(770) 488-8613; facsimile (770) 488-8615; e-mail [email protected]. CRADA 
information, and information related to the technology listed below, 
may be obtained by writing to Kathleen Goedel, Program Analyst, 
Technology Transfer Office, National Institute for Occupational Safety 
and Health (NIOSH), Centers for Disease Control and Prevention (CDC), 
mailstop R-6, 4676 Columbia Parkway, Cincinnati, OH 45226, telephone 
(513) 841-4560; facsimile (513) 458-7170; or e-mail [email protected]. A 
signed Confidential Disclosure Agreement (available under Forms at 
http://www.cdc.gov/tto) will be required to receive copies of 
unpublished patent applications and other information.

Occupational Safety

Cleansing and Removal Method and Technique for Lead Contaminated Dermal 
Surfaces

    Workplace exposure to toxic metals, (i.e., lead, cadmium, and 
arsenic) can cause systemic poisoning and are a recognized health 
threat to thousands of workers in numerous industries. A potentially 
significant, but often overlooked risk for exposures is hand-to-mouth 
transfer due to contaminated hands. Other metals of concern include 
chromium and nickel, which are potential skin sensitizers that can have 
significant and long-term health consequences for those affected. 
Prevention of skin exposures should be the primary course of action, 
but effective removal of metals from skin becomes necessary when dermal 
exposures cannot be completely controlled, and when the efficacy of 
handwashing is questionable.
    NIOSH/CDC researchers have developed a novel handwipe system for 
removal of certain toxic metals from the skin. Preliminary research 
shows that this new approach is highly effective and performs better 
than traditional handwashing (soap and water) as well as better than 
other commercial

[[Page 52906]]

handwashing products. The new method is easy to use and inherently safe 
to both the user and the environment and has been submitted for patent 
protection.
    CDC/NIOSH is soliciting for a Cooperative Research and Development 
Agreement (CRADA) partner to refine development of this new skin 
cleanser and to license and commercialize the final product. Preferred 
partners will have the ability to conduct testing to verify the safety 
of regular repeated use through a battery of clinical and instrumental 
test procedures aimed at determining skin compatibility. Testing trials 
to assess user acceptance and laboratory evaluations to determine 
product stability are also requested. Preferred partners should also be 
able to propose recommendations to the basic formulation for 
enhancements to user acceptance and final packaging of the end product. 
Preferred partners will have a strong market share and a demonstrated 
business network capable of effective dissemination of the final 
product.
    Patent applications will be filed on new intellectual property 
resulting from the CRADA. The CRADA partner will have an option to 
exclusively license any rights NIOSH/CDC may have in the new 
technology.

Inventors: Esswein, Eric et al.
U.S. Patent Application SN: Not yet filed. (CDC Ref. : I-028-
03).

    Dated: August 23, 2004.
James D. Seligman,
Associate Director for Program Service, Centers for Disease Control and 
Prevention.
[FR Doc. 04-19702 Filed 8-27-04; 8:45 am]
BILLING CODE 4163-18-P